Single Nucleotide Polymorphism rs1800497 in Risperidone and Aripiprazole Therapy for Schizophrenia Patients

Authors

  • Benedictus Wicaksono Widodo Master of Biomedical Science Program, Faculty of Medicine, Sriwijaya University, Palembang, Sumatera Selatan, Indonesia
  • Mgs. M. Irsan Saleh Pharmacology Department, Faculty of Medicine, Sriwijaya University, Palembang, Sumatera Selatan, Indonesia
  • Theodorus Theodorus Pharmacology Department, Faculty of Medicine, Sriwijaya University, Palembang, Sumatera Selatan, Indonesia

DOI:

https://doi.org/10.20527/jps.v8i2.10514

Keywords:

rs1800497, Polymorphism, Schizophrenia

Abstract

Schizophrenia is a variable of psychopathologic syndrome involving cognition, emotion, perception, and other behavioral aspects. Therapies on schizophrenia is solely based on history of mental illnesses and mental status. Schizophrenia affecting 1.1 million persons globally in 2017; 70.8% of them happened in 25-55 years old. This study was conducted in mental hospital in Palembang, Indonesia. Blood samples was taken from clinically diagnosed schizophrenia patients (20 patients taking aripiprazole and 60 patients taking risperidone) under therapy. DNA was extracted using Chelex 100 method and digested using Taq1 enzyme. DNA was electrophoresized and visualized. CC allele was found in 10% of patients taking aripiprazole and 11.67% patients taking risperidone. CT allele was found in 70% patients taking aripiprazole and 76.67% patients taking risperidone. TT allele was found in 20% patients taking aripiprazole and 11.67% patients taking risperidone. ANKK1 Taq1A polymorphism in schizophrenia patients shows different therapeutic response with worse therapeutic response compared to patients with normal allele.

References

Brunton, L., Hilal-Dandan, R., & Knollmann, B. (2018). Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition. McGraw Hill Education.

Bulayeva, K. B., Glatt, S. J., Bulayev, O. A., Pavlova, T. A., & Tsuang, M. T. (2007). Genome-wide linkage scan of schizophrenia: A cross-isolate study. Genomics, 89(2), 167–177. https://doi.org/10.1016/j.ygeno.2006.10.001

Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophrenia Bulletin, 44(6), 1195–1203. https://doi.org/10.1093/schbul/sby058

De Bartolomeis, A., Tomasetti, C., & Iasevoli, F. (2015). Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies beyond Dopamine Receptor Antagonism. CNS Drugs, 29(9), 773–799. https://doi.org/10.1007/s40263-015-0278-3

González-Castro, T. B., Hernández-Díaz, Y., Juárez-Rojop, I. E., López-Narváez, M. L., Tovilla-Zárate, C. A., Genis-Mendoza, A., & Alpuin-Reyes, M. (2016). The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: Systematic review and meta-analysis. In Behavioral and Brain Functions (Vol. 12, Issue 1, pp. 1–14). BioMed Central. https://doi.org/10.1186/s12993-016-0114-z

Grant, S., & Fitton, A. (1994). Risperidone. Drugs, 48(2), 253–273. https://doi.org/10.2165/00003495-199448020-00009

He, M., Yan, H., Duan, Z. X., Qu, W., Gong, H. Y., Fan, Z. L., Kang, J. Y., Li, B. C., & Wang, J. M. (2013). Genetic distribution and association analysis of DRD2 gene polymorphisms with major depressive disorder in the Chinese Han population. International Journal of Clinical and Experimental Pathology, 6(6), 1142–1149.

Katzung, B. G. (2018). Basic and Clinical Pharmacology (14th ed.). McGraw Hill Education. https://linkinghub.elsevier.com/retrieve/pii/S0378608019300108

Klein, T. A., Neumann, J., Reuter, M., Hennig, J., Von Cramon, D. Y., & Ullsperger, M. (2007). Genetically determined differences in learning from errors. Science, 318(5856), 1642–1645. https://doi.org/10.1126/science.1145044

Kwon, J. S., Kim, E., Kang, D. H., Choi, J. S., Yu, K. S., Jang, I. J., Shin, S. G., & APLUS study group. (2008). Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. European Neuropsychopharmacology, 18(12), 897–907. https://doi.org/10.1016/j.euroneuro.2008.07.010

Metrics, G. H. (2019). Global , regional , and national incidence , prevalence , and years lived with disability for 354 diseases and injuries for 195 countries and territories , 1990 – 2017 : a systematic analysis for the Global Burden of Disease Study 2017. 1990–2017. https://doi.org/10.1016/S0140-6736(18)32279-7

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry, 10(1), 79–104. https://doi.org/10.1038/sj.mp.4001556

Mota, N. R., Araujo-Jnr, E. V., Paixão-Côrtes, V. R., Bortolini, M. C., & Bau, C. H. D. (2012). Linking dopamine neurotransmission and neurogenesis: The evolutionary history of the NTAD (NCAM1-TTC12-ANKK1-DRD2) gene cluster. Genetics and Molecular Biology, 35(4 SUPPL.), 912–918. https://doi.org/10.1590/S1415-47572012000600004

Murray, G. K., Corlett, P. R., Clark, L., Pessiglione, M., Blackwell, A. D., Honey, G., Jones, P. B., Bullmore, E. T., Robbins, T. W., & Fletcher, P. C. (2008). How dopamine dysregulation leads to psychotic symptoms? Abnormal mesolimbic and mesostriatal prediction error signalling in psychosis. Molecular Psychiatry, 13(3), 239. https://doi.org/10.1038/sj.mp.4002157

Neve, K. A., Seamans, J. K., & Trantham-Davidson, H. (2004). Dopamine receptor signaling. Journal of Receptors and Signal Transduction, 24(3), 165–205. https://doi.org/10.1081/RRS-200029981

Neville, M. J., Johnstone, E. C., & Walton, R. T. (2004). Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation, 23(6), 540–545. https://doi.org/10.1002/humu.20039

Sadock, B. J., & Sadock, V. A. (2010). Concise Textbook of Clinical Psychiatry.

Sáiz, P. A., García-Portilla, M. P., Arango, C., Morales, B., Arias, B., Corcoran, P., Fernández, J. M., Alvarez, V., Coto, E., Bascarán, M. T., Bousoño, M., Fañanas, L., & Bobes, J. (2010). Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(1), 26–31. https://doi.org/10.1016/j.pnpbp.2009.09.008

Seo, D., Patrick, C. J., & Kennealy, P. J. (2008). Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggression and Violent Behavior, 13(5), 383–395. https://doi.org/10.1016/j.avb.2008.06.003

Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L. X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28(8), 1400–1411. https://doi.org/10.1038/sj.npp.1300203

Shen, Y. C., Chen, S. F., Chen, C. H., Lin, C. C. H., Chen, S. J., Chen, Y. J., & Luu, S. U. (2009). Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of Psychiatric Research, 43(6), 600–606. https://doi.org/10.1016/j.jpsychires.2008.09.005

Vijayan, N. N., Bhaskaran, S., Koshy, L. V, Natarajan, C., Srinivas, L., Nair, C. M., Allencherry, P. M., & Banerjee, M. (2007). Behavioral and Brain Functions Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. 12, 1–12. https://doi.org/10.1186/1744-9081-3-34

Volkow, N. D., Wang, G. J., Fowler, J. S., & Telang, F. (2008). Overlapping neuronal circuits in addiction and obesity: Evidence of systems pathology. Philosophical Transactions of the Royal Society B: Biological Sciences, 363(1507), 3191–3200. https://doi.org/10.1098/rstb.2008.0107

Yao, J., Pan, Y. qing, Ding, M., Pang, H., & Wang, B. jie. (2015). Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: A meta-analysis. In American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics (Vol. 168, Issue 1, pp. 1–13). https://doi.org/10.1002/ajmg.b.32281

Ye, J., Ji, F., Jiang, D., Lin, X., Chen, G., & Zhang, W. (2019). Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment. 13(April), 1–9. https://doi.org/10.3389/fnins.2019.00355

Zhang, C., Zhang, J., Fan, J., Cheng, W., Du, Y., Yu, S., & Fang, Y. (2014). Identification of ANKK1 rs1800497 variant in schizophrenia: New data and meta-analysis. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 165(7), 564–571. https://doi.org/10.1002/ajmg.b.32259

Zhang, H., Wang, W., Zhao, Z., Ge, Y., Zhang, J., Yu, D., Chai, W., Wu, S., & Xu, L. (2010). The action sites of propofol in the normal human brain revealed by functional magnetic resonance imaging. Anatomical Record, 293(12), 1985–1990. https://doi.org/10.1002/ar.21289

Zhang, J. P., Robinson, D. G., Gallego, J. A., John, M., Yu, J., Addington, J., Tohen, M., Kane, J. M., Malhotra, A. K., & Lencz, T. (2015). Association of a Schizophrenia Risk Variant at the DRD2 Locus with Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia Bulletin, 41(6), 1248–1255. https://doi.org/10.1093/schbul/sbv116

Downloads

Additional Files

Published

2021-10-27

Issue

Vol. 8 No. 2 (2021): Jurnal Pharmascience

Section

Jurnal Pharmascience

License

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.